Edo Vellenga

39.9k total citations · 2 hit papers
487 papers, 18.7k citations indexed

About

Edo Vellenga is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Edo Vellenga has authored 487 papers receiving a total of 18.7k indexed citations (citations by other indexed papers that have themselves been cited), including 265 papers in Hematology, 179 papers in Molecular Biology and 167 papers in Oncology. Recurrent topics in Edo Vellenga's work include Acute Myeloid Leukemia Research (142 papers), Hematopoietic Stem Cell Transplantation (64 papers) and Multiple Myeloma Research and Treatments (59 papers). Edo Vellenga is often cited by papers focused on Acute Myeloid Leukemia Research (142 papers), Hematopoietic Stem Cell Transplantation (64 papers) and Multiple Myeloma Research and Treatments (59 papers). Edo Vellenga collaborates with scholars based in Netherlands, United States and Belgium. Edo Vellenga's co-authors include Jan Jacob Schuringa, Elisabeth G.E. de Vries, W. Kruijer, Albertus T.J. Wierenga, Bob Löwenberg, Willem A. Kamps, Eveline S.J.M. de Bont, Hein Schepers, Gerald de Haan and J. Th. M. de Wolf and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Edo Vellenga

481 papers receiving 18.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. profile →
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

2011 441 citations Edo Vellenga et al. Blood profile →

Peers

Countries citing papers authored by Edo Vellenga

Since Specialization

Citations

This map shows the geographic impact of Edo Vellenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edo Vellenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edo Vellenga more than expected).

Fields of papers citing papers by Edo Vellenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edo Vellenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edo Vellenga. The network helps show where Edo Vellenga may publish in the future.

Co-authorship network of co-authors of Edo Vellenga

This figure shows the co-authorship network connecting the top 25 collaborators of Edo Vellenga. A scholar is included among the top collaborators of Edo Vellenga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edo Vellenga. Edo Vellenga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation 2021 ·Bone Marrow Transplantation ·(unknown), (unknown), Walter J. F. M. van der Velden, Joop H. Jansen, Brigitte Bär, Nicolaas Schaap, (unknown), André B. Mulder, Marco R. de Groot, Frédéric Baron, Edo Vellenga, (unknown), Gerwin Huls	7
2	Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15) 2017 ·Blood ·(unknown), Dana Chiţu, Violaine Havelange, Mojca Jongen‐Lavrencic, (unknown), Bart J. Biemond, (unknown), (unknown), Carlos Graux, (unknown), Okke de Weerdt, Dimitri Breems, Saskia K. Klein, Jürgen Kuball, Gert J. Ossenkoppele, Bob Löwenberg, Edo Vellenga	5
3	Progression of a solitary plasmacytoma to multiple myeloma. A population‐based registry of the northern Netherlands 2016 ·British Journal of Haematology ·(unknown), (unknown), Nic J.G.M. Veeger, (unknown), Francisca Ong, Wilma G.J.M. Smit, Sjoerd Hovenga, Mels Hoogendoorn, M. C. H. Hogenes, Max Beijert, Arjan Diepstra, Edo Vellenga	40
4	Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions 2016 ·Stem Cells and Development ·(unknown), Maurien Pruis, Edo Vellenga, Jan Jacob Schuringa	8
5	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology 2015 ·Haematologica ·Bouke P. C. Hazenberg, Alexandra Croockewit, Bronno van der Holt, Sonja Zweegman, Gerard M.J. Bos, (unknown), Reinier Raymakers, (unknown), Edo Vellenga, P. Wijermans, Peter A. von dem Borne, M. H. van Oers, Okke de Weerdt, (unknown), H M Lokhorst, (unknown)	16
6	Radionuclide imaging of bone marrow disorders 2010 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Andor W.J.M. Glaudemans, Hendrikus H. Boersma, Rudi Dierckx, Edo Vellenga, Riemer H. J. A. Slart	54
7	Bone Marrow Dysfunction in Chronic Heart Failure Patients 2010 ·European Journal of Heart Failure ·B. Daan Westenbrink, Adriaan A. Voors, Rudolf A. de Boer, Jan Jacob Schuringa, Theo J. Klinkenberg, Pim van der Harst, Edo Vellenga, Dirk J. van Veldhuisen, Wiek H. van Gilst	84
8	Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria 2009 ·Leukemia ·Ewout J. Houwerzijl, (unknown), Nel R. Blom, J.J.L. van der Want, (unknown), Edo Vellenga	45
9	Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma 2006 ·Blood ·(unknown), Josée M. Zijlstra, Wim J. Sluiter, Gustaaf W. van Imhoff, Jan Pruim, Willem Vaalburg, Edo Vellenga	96
10	Oncogenic Ras blocks transforming growth factor-β–induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway 2005 ·Experimental Hematology ·Hein Schepers, Albertus T.J. Wierenga, Bart J. L. Eggen, Edo Vellenga	12
11	Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia 2005 ·Clinical Cancer Research ·Sabine Plasschaert, Eveline S.J.M. de Bont, Marike Boezen, (unknown), (unknown), Klaas Nico Faber, Willem A. Kamps, Elisabeth G.E. de Vries, Edo Vellenga	88
12	Peripheral Blood Stem Cells Differ from Bone Marrow Stem Cells in Cell Cycle Status, Repopulating Potential, and Sensitivity Toward Hyperthermic Purging in Mice Mobilized with Cyclophosphamide and Granulocyte Colony-Stimulating Factor 2002 ·Journal of Hematotherapy & Stem Cell Research ·Pieter K. Wierenga, Rita Setroikromo, (unknown), Harm H. Kampinga, Edo Vellenga	12
13	A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) 2001 ·Blood ·GJ Ossenkoppele, Bronno van der Holt, Pieter Sonneveld, Edo Vellenga, (unknown), Douwe H. Biesma, Petra H.M. Westveer, Georg Peters, Paul Noordhuis, Petra Muus, Wilfried J. Graveland, M Schaafsma, Dominik Selleslag, Michel Delforge, Bob Löwenberg, Gregor Verhoef	2
14	P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. 2000 ·PubMed ·(unknown), Elisabeth G.E. de Vries, (unknown), (unknown), G.J. Ossenkoppele, G. Verhoef, Edo Vellenga	84
15	Differential effects of interleukin-3 and interleukin-1 on the proliferation and interleukin-6 protein secretion of acute myeloid leukemic cells; the involvement of ERK, p38 and STAT5. 1999 ·PubMed ·(unknown), MT Esselink, W. Kruijer, Edo Vellenga	16
16	P-gp and mrp activities in relation to treatment outcome in acute myeloid leukemia. 1999 ·Data Archiving and Networked Services (DANS) ·Elisabeth G.E. de Vries, WLJ van Putten, (unknown), (unknown), (unknown), Pieter Sonneveld, Bob Löwenberg, Edo Vellenga	1
17	Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. 1998 ·PubMed ·Dorina M. van der Kolk, Elisabeth G.E. de Vries, (unknown), Anke van den Berg, Michael Müller, Edo Vellenga	79
18	Signaling through CD5 Activates a Pathway Involving Phosphatidylinositol 3-Kinase, Vav, and Rac1 in Human Mature T Lymphocytes 1998 ·Molecular and Cellular Biology ·Sonja I. Gringhuis, Lou F. M. H. de Leij, Paul J. Coffer, Edo Vellenga	66
19	Transcriptional regulation of interleukin-6 gene expression in acute myeloid leukemia blasts with constitutive cytokine production 1996 ·Data Archiving and Networked Services (DANS) ·Leonore Tuyt, (unknown), (unknown), (unknown), (unknown), Edo Vellenga	1
20	The spontaneous expression of interleukin-1 beta and interleukin-6 is associated with spontaneous expression of AP-1 and NF-kappa B transcription factor in acute myeloblastic leukemia cells. 1995 ·University of Groningen research database (University of Groningen / Centre for Information Technology) ·WH Dokter, Leonore Tuyt, (unknown), MT Esselink, Edo Vellenga	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact